| Methods |
1‐ to 2‐week washout period for patients who were currently receiving antihypertensive therapy; 2‐ to 4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐115 mm Hg during 2 consecutive weeks of run‐in; also required that ambulatory awake DBP >/= 85 mm Hg; total 8‐week double‐blind treatment: 4‐week low‐dose treatment (week 0‐4), forced titration at week 4 to high‐dose, 4‐week high‐dose treatment (week 4‐8) |
| Participants |
Enalapril 10 mg: n=99(58 males,41 females); mean age=54(10) years; baseline SBP=145(16) mm Hg, DBP=93(8) mm Hg; baseline HR=72(10) bpm;
Placebo: n=46(30 males,16 females); mean age=56(11) years; baseline SBP=148(12) mm Hg, DBP=95(6) mm Hg; baseline HR=71(9) bpm |
| Interventions |
Enalapril 10 mg once daily;
Placebo;
administered in the morning |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
Used week 4 BP data only; BP change and SD of change reported, endpoint BP and SD not reported; BP data from Table IV, p. 663; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
